Financials data is unavailable for this security.
View more
Year on year GlaxoSmithKline Pharmaceuticals Ltd had net income fall -3.39% from 6.11bn to 5.90bn despite revenues that grew 6.21% from 32.52bn to 34.54bn over the same period.
| Gross margin | 61.97% |
|---|---|
| Net profit margin | 18.25% |
| Operating margin | 21.74% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, GlaxoSmithKline Pharmaceuticals Ltd increased its cash reserves by 83.66%, or 292.30m. The company earned 5.82bn from its operations for a Cash Flow Margin of 16.85%. In addition the company generated 87.12m cash from investing, though they paid out 5.61bn more in financing than they received.
| Cash flow per share | 41.89 |
|---|---|
| Price/Cash flow per share | 66.80 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -2.91%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.92% |
|---|---|
| Div growth rate (5 year) | 9.86% |
| Payout ratio (TTM) | 84.70% |
| EPS growth(5 years) | 5.78 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 2.59 |
More ▼
